

Filed: February 26, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

TEVA PHARMACEUTICALS USA, INC.,  
Petitioner,

v.

INDIVIOR UK LIMITED,  
Patent Owner.

---

Case IPR2016-00280  
Patent 8,475,832

---

**PETITIONER'S UPDATED EXHIBIT LIST**

Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits the following current exhibit list:

Exhibit No.	Reference
1001	U.S. Patent No. 8,475,832 (filed August 7, 2009)
1002	File History, U.S. Patent No. 8,475,832
1003	Expert Declaration of Nandita Das, Ph.D., Relating to U.S. Patent No. 8,475,832
1004	U.S. Patent Application Publication 2005/0085440 (published April 21, 2005) (“Birch”)
1005	WO 2008/025791 (published March 6, 2008) (“Oksche”)
1006	U.S. Patent No. 7,357,891 (published December 23, 2004) (issued April 15, 2008) (“Yang”)
1007	WO 2008/040534 (published April 10, 2008) (“LabTec”)
1008	Suboxone® Label
1009	Suboxone® Tablet Summary Basis of Approval (“SBOA”)
1010	U.S. Patent Application Publication No. 2005/0037055 (“the ’055 publication”)
1011	European Medicines Agency Initial Marketing-Authorisation Document, Scientific Discussion, Oct. 19, 2006 for Suboxone sublingual tablets (“EMEA”)
1012	J.P. Cassidy et al., <i>Controlled Buccal Delivery of Buprenorphine</i> , 25 J. Controlled Release 21 (1993)
1013	Rex M. C. Dawson et al., <i>Data for Biochemical Research</i> (3d ed. 1986)

1014	Domenic A. Ciraulo et al., <i>Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials</i> , 46 J. Clinical Pharmacology 179 (2006)
1015	C. Nora Chiang & Richard L. Hawks, <i>Pharmacokinetics of the Combination Tablet of Buprenorphine and Naloxone</i> , 70 Drug & Alcohol Dependence S39 (2003)
1016	Campbell et al., <i>The History of the Development of Buprenorphine as an Addiction Therapeutic</i> , 1248 Ann. N.Y. Acad. Sc. (Issue: <i>Addiction Reviews</i> ), 124 (2012) (“Campbell”)
1017	Bullingham et al., <i>Sublingual Buprenorphine Used Postoperatively: Clinical Observations and Preliminary Pharmacokinetic Analysis</i> , 12 Br. J. Clinical Pharmacology 117 (1981)
1018	U.S. Patent App. No. US 2010/0087470
1019	U.S. Patent No. 4,582,835
1020	Center for Drug Evaluation and Research, Approval Package for App. No. 22-410/S006/S007 (approval date 8/10/12) (“Film Approval Package”)
1021	Encyclopedia of Pharmaceutical Technology, 2 <sup>nd</sup> ed., Vol. I, Drug Delivery—Buccal Route (McElnay et al.) (“McElnay”)
1022	U.S. Patent No. 5,288,497 (“Stanley”)
1023	Declaration by Maureen Reitman, SC.D. (“Reitman Decl.”)
1024	Parkhurst A. Shore et al., <i>The Gastric Secretion of Drugs: A pH Partition Hypothesis</i> , 119 J. Pharmacology Exp. Ther. 361 (1957)
1025	Curriculum Vitae of Nandita Das, Ph.D.
1026	List of Materials Considered by Nandita Das, Ph.D.
1027	Telephone Conference Transcript, <i>Teva Pharmaceuticals USA, Inc. v. Monsol RX LLC and Indivior</i> , IPR2016-00280, IPR2016-00281, and IPR2016-00282 (Feb. 17, 2016)

Pursuant to the Board's directive during the parties' February 17, 2016 call with the Board, Petitioner herewith files Exhibit 1027, Telephone Conference Transcript, *Teva Pharmaceuticals USA, Inc. v. Monsol RX LLC and Indivior*, IPR2016-00280, IPR2016-00281, and IPR2016-00282 (Feb. 17, 2016).

Dated: February 26, 2016

Respectfully submitted,

/Elizabeth J. Holland/  
Elizabeth J. Holland (Reg. No. 47,657)  
Goodwin Procter LLP  
The New York Times Building  
620 Eighth Avenue  
New York, NY 10018  
Tel: 212-813-8800  
Fax: 212-355-3333

*Counsel for Petitioner*

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that the foregoing: **PETITIONER'S UPDATED EXHIBIT LIST** and accompanying Exhibit 1027 were served electronically via e-mail on February 26, 2016 on the following:

Andrea G. Reister

areister@cov.com

Enrique D. Longton

rlongton@cov.com

Dated: February 26, 2016

By: /Cynthia Lambert Hardman/  
Cynthia Lambert Hardman  
(Reg. No. 53,179)